JP2018515513A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018515513A5 JP2018515513A5 JP2017558542A JP2017558542A JP2018515513A5 JP 2018515513 A5 JP2018515513 A5 JP 2018515513A5 JP 2017558542 A JP2017558542 A JP 2017558542A JP 2017558542 A JP2017558542 A JP 2017558542A JP 2018515513 A5 JP2018515513 A5 JP 2018515513A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- antibody according
- seq
- region
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004965 antibodies Human genes 0.000 claims 9
- 108090001123 antibodies Proteins 0.000 claims 9
- UREBDLICKHMUKA-CXSFZGCWSA-N Dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 2
- 229960003957 Dexamethasone Drugs 0.000 claims 2
- 230000003442 weekly Effects 0.000 claims 1
Claims (8)
- CD38に特異的な抗体において、多発性骨髄腫の処置に用いられる配列GFTFSSYYMN(配列番号1)またはSYYMN(配列番号2)のHCDR1領域、配列GISGDPSNTYYADSVKG(配列番号3)のHCDR2領域、配列DLPLVYTGFAY(配列番号4)のHCDR3、配列SGDNLRHYYVY(配列番号5)のLCDR1領域、配列GDSKRPS(配列番号6)のLCDR2領域、および配列QTYTGGASL(配列番号7)のLCDR3領域を含み、8mg/kg以上の用量にて、少なくとも8週にわたって、週1回(q1w)投与されることを特徴とする抗体。
- 請求項1に記載の抗体において、16mg/kg以上の用量にて投与されることを特徴とする抗体。
- 請求項1乃至2の何れか1項に記載の抗体において、静脈内に投与されることを特徴とする抗体。
- 請求項1乃至3の何れか1項に記載の抗体において、2時間にわたって、静脈内に投与されることを特徴とする抗体。
- 請求項1乃至5の何れか1項に記載の抗体において、IgG1 Fc領域を含むことを特徴とする抗体。
- 請求項1乃至6の何れか1項に記載の抗体において、デキサメタゾンと組み合わせて投与されることを特徴とする抗体。
- 請求項7に記載の抗体において、デキサメタゾンと組み合わせて投与され、デキサメタゾンは、週1回(q1W)、20mgまたは40mgにて投薬されることを特徴とする、抗体。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021078658A JP2021130668A (ja) | 2015-05-13 | 2021-05-06 | 多発性骨髄腫(mm)の処置 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15167597.2 | 2015-05-13 | ||
EP15167597 | 2015-05-13 | ||
PCT/EP2016/060810 WO2016180958A1 (en) | 2015-05-13 | 2016-05-13 | Treatment for multiple myeloma (mm) |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021078658A Division JP2021130668A (ja) | 2015-05-13 | 2021-05-06 | 多発性骨髄腫(mm)の処置 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2018515513A JP2018515513A (ja) | 2018-06-14 |
JP2018515513A5 true JP2018515513A5 (ja) | 2019-06-13 |
JP7160533B2 JP7160533B2 (ja) | 2022-10-25 |
Family
ID=53174925
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017558542A Active JP7160533B2 (ja) | 2015-05-13 | 2016-05-13 | 多発性骨髄腫(mm)の処置 |
JP2021078658A Pending JP2021130668A (ja) | 2015-05-13 | 2021-05-06 | 多発性骨髄腫(mm)の処置 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021078658A Pending JP2021130668A (ja) | 2015-05-13 | 2021-05-06 | 多発性骨髄腫(mm)の処置 |
Country Status (23)
Country | Link |
---|---|
US (2) | US10533057B2 (ja) |
EP (1) | EP3294769B1 (ja) |
JP (2) | JP7160533B2 (ja) |
KR (1) | KR20180008571A (ja) |
CN (1) | CN107614530A (ja) |
AU (1) | AU2016260895B2 (ja) |
CA (1) | CA2984464C (ja) |
CY (1) | CY1123982T1 (ja) |
DK (1) | DK3294769T3 (ja) |
ES (1) | ES2862708T3 (ja) |
HR (1) | HRP20210552T1 (ja) |
HU (1) | HUE054271T2 (ja) |
IL (1) | IL255552B (ja) |
LT (1) | LT3294769T (ja) |
MX (1) | MX2017014396A (ja) |
PL (1) | PL3294769T3 (ja) |
PT (1) | PT3294769T (ja) |
RS (1) | RS61668B1 (ja) |
RU (1) | RU2723047C2 (ja) |
SG (1) | SG11201708691VA (ja) |
SI (1) | SI3294769T1 (ja) |
WO (1) | WO2016180958A1 (ja) |
ZA (1) | ZA201708386B (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LT3294769T (lt) * | 2015-05-13 | 2021-04-26 | Morphosys Ag | Daugybinei mielomai (dm) skirtas gydymas |
CN110144008B (zh) * | 2018-02-12 | 2021-03-19 | 杭州尚健生物技术有限公司 | Cd38蛋白抗体及其应用 |
WO2019186273A1 (en) * | 2018-03-28 | 2019-10-03 | Takeda Pharmaceutical Company Limited | Subcutaneous dosing of anti-cd38 antibodies |
CN109265551B (zh) * | 2018-09-25 | 2020-09-15 | 华东师范大学 | Cd38抗体、嵌合抗原受体和药物 |
WO2020120730A1 (en) * | 2018-12-14 | 2020-06-18 | Morphosys Ag | Antibody formulations |
MX2021009079A (es) * | 2019-01-28 | 2022-02-10 | Sanofi Sa | Metodos para tratar el mieloma multiple. |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020164788A1 (en) | 1994-12-02 | 2002-11-07 | The Wellcome Foundation Limited | Humanized antibodies to CD38 |
WO1999062526A2 (en) | 1998-06-05 | 1999-12-09 | Mayo Foundation For Medical Education And Research | Use of genetically engineered antibodies to cd38 to treat multiple myeloma |
EP1174440A1 (en) | 2000-07-19 | 2002-01-23 | U-BISys B.V. | A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment |
WO2006125640A2 (en) | 2005-05-24 | 2006-11-30 | Morphosys Ag | Generation and profiling of fully human hucal gold®-derived therapeutic antibodies specific for human cd38 |
ES2541489T3 (es) | 2004-02-06 | 2015-07-21 | Morphosys Ag | Anticuerpos humanos anti-CD38 y usos para ellos |
US8263746B2 (en) | 2004-02-06 | 2012-09-11 | Morphosys Ag | Anti-CD38 human antibodies and uses thereof |
CN101218256B (zh) | 2005-03-23 | 2017-04-19 | 根马布股份公司 | 用于治疗多发性骨髓瘤的cd38抗体 |
KR101472250B1 (ko) | 2005-10-12 | 2014-12-11 | 모르포시스 아게 | 인간 cd38에 특이적인 완전 인간 hucal gold-유도 치료 항체들의 생성 및 프로파일링 |
EP3115049A1 (en) * | 2006-08-07 | 2017-01-11 | AbbVie Biotherapeutics Inc. | Combination therapies based on anti-cs1 antibodies for treating multiple myeloma |
US9040050B2 (en) * | 2006-09-26 | 2015-05-26 | Genmab A/S | Combination treatment of CD38-expressing tumors |
EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
WO2011154453A1 (en) * | 2010-06-09 | 2011-12-15 | Genmab A/S | Antibodies against human cd38 |
BR112013006769B1 (pt) | 2010-09-27 | 2021-02-02 | Morphosys Ag | combinação sinérgica |
US9738933B2 (en) * | 2012-12-05 | 2017-08-22 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | RNF41 as a biomarker predicting response to lenalidomide in non-del(5q) MDS |
CN103421115B (zh) * | 2013-09-02 | 2015-06-03 | 东南大学 | 一种cd38纳米抗体及应用 |
TW201522378A (zh) * | 2013-10-31 | 2015-06-16 | Sanofi Sa | 用於治療人類癌症的特異性抗cd38抗體 |
CN106604750B (zh) | 2014-06-16 | 2021-05-07 | 梅约医学教育与研究基金会 | 治疗骨髓瘤 |
WO2016022589A2 (en) * | 2014-08-08 | 2016-02-11 | The Regents Of The University Of California | Methods for treating multiple myeloma |
SG11201701867SA (en) | 2014-09-09 | 2017-04-27 | Janssen Biotech Inc | Combination therapies with anti-cd38 antibodies |
LT3294769T (lt) * | 2015-05-13 | 2021-04-26 | Morphosys Ag | Daugybinei mielomai (dm) skirtas gydymas |
-
2016
- 2016-05-13 LT LTEP16723349.3T patent/LT3294769T/lt unknown
- 2016-05-13 CA CA2984464A patent/CA2984464C/en active Active
- 2016-05-13 KR KR1020177035726A patent/KR20180008571A/ko not_active Application Discontinuation
- 2016-05-13 JP JP2017558542A patent/JP7160533B2/ja active Active
- 2016-05-13 SG SG11201708691VA patent/SG11201708691VA/en unknown
- 2016-05-13 EP EP16723349.3A patent/EP3294769B1/en active Active
- 2016-05-13 PL PL16723349T patent/PL3294769T3/pl unknown
- 2016-05-13 MX MX2017014396A patent/MX2017014396A/es unknown
- 2016-05-13 CN CN201680027238.0A patent/CN107614530A/zh active Pending
- 2016-05-13 AU AU2016260895A patent/AU2016260895B2/en active Active
- 2016-05-13 RU RU2017137496A patent/RU2723047C2/ru active
- 2016-05-13 ES ES16723349T patent/ES2862708T3/es active Active
- 2016-05-13 HU HUE16723349A patent/HUE054271T2/hu unknown
- 2016-05-13 WO PCT/EP2016/060810 patent/WO2016180958A1/en active Application Filing
- 2016-05-13 PT PT167233493T patent/PT3294769T/pt unknown
- 2016-05-13 SI SI201631139T patent/SI3294769T1/sl unknown
- 2016-05-13 DK DK16723349.3T patent/DK3294769T3/da active
- 2016-05-13 US US15/569,495 patent/US10533057B2/en active Active
- 2016-05-13 RS RS20210419A patent/RS61668B1/sr unknown
-
2017
- 2017-11-09 IL IL255552A patent/IL255552B/en unknown
- 2017-12-11 ZA ZA2017/08386A patent/ZA201708386B/en unknown
-
2019
- 2019-11-25 US US16/693,904 patent/US11591406B2/en active Active
-
2021
- 2021-03-30 CY CY20211100276T patent/CY1123982T1/el unknown
- 2021-04-07 HR HRP20210552TT patent/HRP20210552T1/hr unknown
- 2021-05-06 JP JP2021078658A patent/JP2021130668A/ja active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2018515513A5 (ja) | ||
PE20200294A1 (es) | Anticuerpos que se unen especificamente a pd-1 y metodos de uso | |
HRP20171992T1 (hr) | Protutijela protiv cgrp | |
JP2016520514A5 (ja) | ||
AR110203A1 (es) | Anticuerpos anti-tim-3 para combinación con anticuerpos anti-pd-1 | |
PE20200011A1 (es) | ANTICUERPOS ANTI-PEPTIDO BETA AMILOIDE N3pGlu Y SUS USOS | |
JP2018021031A5 (ja) | ||
JP2013542194A5 (ja) | ||
MX2019007848A (es) | Anticuerpos anti-pd-1 y usos de los mismos. | |
NZ610294A (en) | Human antibodies to human tnf-like ligand 1a (tl1a) | |
AU2016204274A1 (en) | Antibodies that bind to OX40 and their uses | |
NZ729158A (en) | Anti-ctla4 monoclonal antibody or antigen binding fragment thereof, medicinal composition and use | |
JP2017505125A5 (ja) | ||
PE20161571A1 (es) | Anticuerpos anti-ox40 y metodos de uso | |
JP2015530399A5 (ja) | ||
ES2687282T3 (es) | Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos | |
NZ631007A (en) | Anti-c5 antibodies having improved pharmacokinetics | |
NZ628528A (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
JP2015535828A5 (ja) | ||
PE20150025A1 (es) | Anticuerpos e inmunoconjugados contra ly6e y metodos de uso | |
AR103713A1 (es) | Anticuerpos contra tau y sus usos | |
PE20090161A1 (es) | Anticuerpos monoclonales anti cxcl13 | |
CO6230999A2 (es) | Anticuerpo anti-esclerostina | |
NZ740221A (en) | St2l antagonists and methods of use | |
NZ628943A (en) | Human antibodies to clostridium difficile toxins |